Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report.

Psychiatry and clinical neurosciences - 1 Aug 2005

Kato Daiji, Kawanishi Chiaki, Kishida Ikuko, Furuno Taku, Matsumura Takehiko, Hasegawa Hana, Suzuki Kyoko, Hirayasu Yoshio

Abstract excerpt

Neuroleptic malignant syndrome (NMS) is a potentially fatal adverse reaction to psychopharmacologic treatment. Reported herein are two NMS patients with schizophrenia who were found to possess a CYP2D6 gene deletion allele (CYP2D6*5). The deletion results in decreased CYP2D6 activity, possibly le...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Alleles
Share to Antipsychotic Agents
Share to Cytochrome P-450 CYP2D6

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Deletion

Share to Polymorphism, Restriction Fragment Length

Share to Reverse Transcriptase Polymerase Chain Reaction

Share to Schizophrenia

Source

Identifiers

PMID: 16048458
DOI: 10.1111/j.1440-1819.2005.01405.x

Genes

NMS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16048458-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

CYP2D6 gene deletion allele in patients with neuroleptic malignant syndrome: preliminary report.PMID 16048458Read ↗

Deletion of the CYP2D6 gene as a likely explanation for the serious side effects of the antipsychotic drug pimozide: a case reportSemantic proximity Read ↗

Effects of CYP2D6 polymorphisms on neuroleptic malignant syndrome.Semantic proximity Read ↗

CYP2D6 polymorphisms and the risk of tardive dyskinesia in schizophrenia: a meta-analysis.Semantic proximity Read ↗

Neuroleptic malignant syndrome in an adolescent with CYP2D6 deficiency.Semantic proximity Read ↗

CYP2D6 genotype and antipsychotic-induced extrapyramidal side effects in schizophrenic patients.Semantic proximity Read ↗

Identification of CYP2D6 null variants among long-stay, chronic psychiatric inpatients: is it strictly necessary?Semantic proximity Read ↗

CYP2D6 polymorphism and tardive dyskinesia in schizophrenic patients.Semantic proximity Read ↗

Genetic predisposition to neuroleptic malignant syndrome : implications for antipsychotic therapy.Semantic proximity Read ↗

CYP2D6 genotyping in patients on psychoactive drug therapy.Semantic proximity Read ↗

A case study: neuroleptic malignant syndrome with risperidone and CYP2D6 gene variation.Semantic proximity Read ↗

Neuroleptic malignant syndrome and hydroxylase gene mutations: no association with CYP2D6A or CYP2D6B.Semantic proximity Read ↗

CYP2D6 mutations and therapeutic outcome in schizophrenic patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.